Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Flavobacteriaceae | 4 | 2024 | 4 | 0.520 |
Why?
|
| Levofloxacin | 2 | 2024 | 13 | 0.410 |
Why?
|
| Fluoroquinolones | 2 | 2024 | 34 | 0.400 |
Why?
|
| Head and Neck Neoplasms | 3 | 2025 | 168 | 0.350 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2024 | 205 | 0.300 |
Why?
|
| Anti-Bacterial Agents | 4 | 2024 | 790 | 0.290 |
Why?
|
| Delphi Technique | 2 | 2025 | 101 | 0.280 |
Why?
|
| DNA Gyrase | 2 | 2024 | 10 | 0.270 |
Why?
|
| Ciprofloxacin | 2 | 2024 | 26 | 0.270 |
Why?
|
| Consensus | 2 | 2025 | 208 | 0.260 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2025 | 58 | 0.260 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 92 | 0.250 |
Why?
|
| Flavobacteriaceae Infections | 2 | 2024 | 2 | 0.250 |
Why?
|
| Jaw Diseases | 1 | 2025 | 2 | 0.230 |
Why?
|
| Osteoradionecrosis | 1 | 2025 | 4 | 0.230 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2025 | 36 | 0.230 |
Why?
|
| Pneumocystis carinii | 1 | 2024 | 8 | 0.220 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2024 | 19 | 0.220 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2024 | 18 | 0.220 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2024 | 6 | 0.210 |
Why?
|
| Global Health | 1 | 2025 | 183 | 0.210 |
Why?
|
| Rifampin | 1 | 2023 | 25 | 0.210 |
Why?
|
| Vancomycin | 1 | 2023 | 39 | 0.210 |
Why?
|
| Hypersensitivity | 1 | 2024 | 64 | 0.200 |
Why?
|
| Biological Products | 1 | 2024 | 96 | 0.200 |
Why?
|
| Rheumatic Fever | 1 | 2022 | 5 | 0.190 |
Why?
|
| Pharyngitis | 1 | 2022 | 13 | 0.190 |
Why?
|
| Arthritis | 1 | 2022 | 53 | 0.190 |
Why?
|
| Antirheumatic Agents | 1 | 2024 | 221 | 0.180 |
Why?
|
| Radiotherapy Dosage | 2 | 2025 | 84 | 0.180 |
Why?
|
| Myocarditis | 1 | 2022 | 67 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 337 | 0.170 |
Why?
|
| Dental Enamel Hypoplasia | 1 | 2020 | 2 | 0.170 |
Why?
|
| Incisor | 1 | 2020 | 7 | 0.170 |
Why?
|
| Mutation | 2 | 2024 | 2612 | 0.150 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 66 | 0.140 |
Why?
|
| Severe Dengue | 1 | 2017 | 24 | 0.130 |
Why?
|
| Proteus Infections | 1 | 2016 | 2 | 0.130 |
Why?
|
| Cephalosporins | 1 | 2016 | 18 | 0.130 |
Why?
|
| Mandible | 1 | 2016 | 9 | 0.130 |
Why?
|
| Internal Medicine | 1 | 2018 | 160 | 0.130 |
Why?
|
| Klebsiella Infections | 1 | 2016 | 22 | 0.130 |
Why?
|
| Radiometry | 1 | 2016 | 36 | 0.130 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 35 | 0.120 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 87 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 94 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2016 | 66 | 0.120 |
Why?
|
| Bacteremia | 1 | 2016 | 94 | 0.120 |
Why?
|
| Neoplasms | 1 | 2025 | 1364 | 0.110 |
Why?
|
| DNA Topoisomerase IV | 2 | 2024 | 3 | 0.100 |
Why?
|
| Humans | 14 | 2025 | 63445 | 0.100 |
Why?
|
| Tumor Burden | 2 | 2025 | 69 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2018 | 808 | 0.080 |
Why?
|
| Child | 3 | 2022 | 4526 | 0.060 |
Why?
|
| Gross Domestic Product | 1 | 2025 | 1 | 0.060 |
Why?
|
| Female | 6 | 2025 | 32880 | 0.060 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2024 | 11 | 0.060 |
Why?
|
| Health Expenditures | 1 | 2025 | 122 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2025 | 141 | 0.050 |
Why?
|
| Genes, rRNA | 1 | 2022 | 8 | 0.050 |
Why?
|
| Male | 5 | 2025 | 29891 | 0.050 |
Why?
|
| Nucleotides | 1 | 2022 | 49 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 88 | 0.050 |
Why?
|
| Fever | 1 | 2022 | 66 | 0.050 |
Why?
|
| Incidence | 1 | 2025 | 1377 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 376 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2022 | 415 | 0.040 |
Why?
|
| Zebrafish | 1 | 2023 | 347 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 2570 | 0.040 |
Why?
|
| Molar | 1 | 2020 | 4 | 0.040 |
Why?
|
| Adult | 3 | 2024 | 16824 | 0.040 |
Why?
|
| Aged | 3 | 2024 | 14447 | 0.040 |
Why?
|
| Adolescent | 2 | 2022 | 6245 | 0.040 |
Why?
|
| Middle Aged | 3 | 2024 | 17613 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2681 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 2017 | 9 | 0.030 |
Why?
|
| Taiwan | 1 | 2017 | 11 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2017 | 29 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 3293 | 0.030 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 2 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1119 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 5462 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1229 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 160 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2018 | 311 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 583 | 0.030 |
Why?
|
| Inpatients | 1 | 2018 | 305 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 730 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 5354 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2017 | 406 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 264 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2334 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 1748 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 1990 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 1364 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4694 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5680 | 0.010 |
Why?
|
| Animals | 1 | 2023 | 20663 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 6658 | 0.010 |
Why?
|